GlassScriptPhysician profile
Nalini Mehtani
NPI 1043364995
$9,452.03
in general payments reported to CMS, 2019-2025
27 companies · $1,576 in 2025
The $1,576 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,708 · 2020: $1,076 · 2021: $357 · 2022: $561 · 2023: $1,606 · 2024: $1,568 · 2025: $1,576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,750.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $1,746.04 | 2019-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $1,371.36 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Janssen Pharmaceuticals, INC | $1,107.31 | 2019-2024 | Spravato, Invega Sustenna |
| Teva Pharmaceuticals USA, INC. | $1,106.81 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Alkermes, INC. | $660.02 | 2019-2025 | Lybalvi, Aristada |
| E.R. Squibb & Sons, L.L.C. | $473.43 | 2022-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $383.44 | 2019-2022 | |
| Clovis Oncology, INC. | $224.48 | 2019 | |
| Biogen, INC. | $223.38 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $218.33 | 2024 | Fanapt |
| Incyte Corporation | $212.55 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $188.15 | 2019-2024 | |
| Neuronetics, INC. | $184.06 | 2023 | Neurostar Tms Therapy System |
| Allergan, INC. | $152.72 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2025 | Caplyta |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $123.50 | 2019 | |
| Gilead Sciences, INC. | $121.87 | 2020 | |
| Glaxosmithkline, LLC. | $119.82 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $118.42 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.77 | 2023 | |
| Amgen INC. | $101.33 | 2019 | |
| Jazz Pharmaceuticals INC. | $100.50 | 2019 | |
| Luye Pharma (USA) LTD. | $96.89 | 2025 | Erzofri Extended-Release |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.37 | 2019 | |
| Lilly USA, LLC | $66.64 | 2024 | |
| Merck Sharp & Dohme LLC | $27.74 | 2019-2020 | |
| Lundbeck LLC | $12.10 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nalini Mehtani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.